|
||||||||
Three
Months
Ended
|
Three
Months
Ended
|
|||||||
March 31,
|
March 31,
|
|||||||
2009
|
2008
|
|||||||
GAAP
Net loss
|
$
|
(1,522,461
|
)
|
$
|
(787,935
|
)
|
||
Adjustments:
|
||||||||
Expense
- non-cash employee compensation
|
1,272,971
|
1,363,803
|
||||||
Expense
- depreciation
|
6,004
|
3,011
|
||||||
Adjusted
Net Income (Loss)
|
$
|
(243,486)
|
$
|
578,879
|
March
31,
|
December
31,
|
|||||||
2009
|
2008
|
|||||||
(Unaudited)
|
||||||||
ASSETS
|
||||||||
Current
Assets
|
||||||||
Cash
and cash equivalents
|
$ | 4,375,361 | $ | 5,580,244 | ||||
Restricted
cash
|
650,000 | 650,000 | ||||||
Accounts
receivable - project revenue and reimbursable project
costs
|
4,319,212 | 5,357,804 | ||||||
Prepaid
expenses & other current assets
|
797,097 | 394,315 | ||||||
Total
Current Assets
|
10,141,670 | 11,982,363 | ||||||
Property
Plant and Equipment –net
|
102,117 | 108,121 | ||||||
Other
Assets
|
||||||||
Patent
costs – net
|
234,277 | 217,875 | ||||||
Security
deposits
|
122,825 | 138,418 | ||||||
Total
Other Assets
|
357,102 | 356,293 | ||||||
Total
Assets
|
$ | 10,600,889 | $ | 12,446,777 | ||||
LIABILITIES
AND STOCKHOLDERS EQUITY
|
||||||||
Current
Liabilities
|
||||||||
Accounts
payable and accrued liabilities
|
$ | 3,542,581 | $ | 5,138,979 | ||||
Total
Liabilities
|
3,542,581 | 5,138,979 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders'
Equity
|
||||||||
Preferred
stock, $0.001 par value, 50,000,000 authorized shares, no shares issued
and outstanding
|
- | - | ||||||
Common
stock, $0.001par value, 500,000,000 authorized, 301,841,722 shares issued
and outstanding at March 31, 2009 and 301,493,084 issued and
outstanding at December 31, 2008
|
301,842 | 301,493 | ||||||
Additional
paid in capital - stock and stock equivalents
|
49,902,488 | 48,607,451 | ||||||
Deficit
|
(43,012,435 | ) | (41,489,974 | ) | ||||
Common
stock reserved for issuance, 152,174 shares and 484,055 shares at March
31, 2009 and December 31, 2008, respectively
|
35,000 | 114,787 | ||||||
Deferred
stock compensation
|
(168,587 | ) | (225,959 | ) | ||||
Total
Stockholders' Equity
|
7,058,308 | 7,307,798 | ||||||
Total
Liabilities and Stockholders' Equity
|
$ | 10,600,889 | $ | 12,446,777 |
Three
Months Ended
|
||||||||
March
31,
|
||||||||
2009
|
2008
|
|||||||
Revenue:
|
||||||||
Consulting
Revenue
|
$ | 2,944,053 | $ | 3,815,125 | ||||
Cost
of Consulting Services Provided
|
1,748,518 | 1,648,004 | ||||||
Gross
Margin
|
1,195,535 | 2,167,121 | ||||||
Operating
Expenses
|
||||||||
General
and administrative
|
1,037,495 | 1,260,186 | ||||||
Research
and development expenses
|
453,805 | 389,521 | ||||||
Stock-based
compensation
|
1,225,186 | 1,363,803 | ||||||
Total
Operating Expenses
|
2,716,486 | 3,013,510 | ||||||
Operating
Loss
|
(1,520,951 | ) | (846,389 | ) | ||||
Other
Income and (Expenses)
|
||||||||
Interest
income
|
3,028 | 89,282 | ||||||
Other
income and expenses
|
(4,538 | ) | 0 | |||||
Total
Other Income and Expenses
|
(1,510 | ) | 89,282 | |||||
Net
Loss before Income Taxes
|
(1,522,461 | ) | (757,107 | ) | ||||
Income
taxes
|
0 | 30,828 | ||||||
Net Loss
|
(1,522,461 | ) | (787,935 | ) | ||||
Other
Comprehensive Income (Loss)
|
||||||||
Unrealized
loss on marketable securities
|
0 | (131,723 | ) | |||||
Total
Comprehensive Loss
|
$ | (1,522,461 | ) | $ | (919,658 | ) | ||
Net
Loss Per Common Share, Basic and diluted
|
$ | (0.01 | ) | $ | (0.00 | ) | ||
Weighted
Average Number of Shares Outstanding For The Period Used To Compute Per
Share Data
|
301,667,403 | 299,064,014 |
Three
months ended
|
||||||||
March
31,
|
||||||||
2009
|
2008
|
|||||||
Operating
Activities:
|
||||||||
Net
Loss
|
$ | (1,522,461 | ) | $ | (787,935 | ) | ||
Adjustments
to reconcile net loss from operations to net cash used in operating
activities:
|
||||||||
Stock
based compensation
|
1,272,971 | 1,363,803 | ||||||
Depreciation
and amortization
|
6,004 | 3,011 | ||||||
Loss
on marketable securities - available for sale
|
0 | (131,723 | ) | |||||
Changes
in non-cash operating working capital items:
|
||||||||
Accounts
receivable - fees and reimbursable project costs
|
1,038,592 | 0 | ||||||
Prepaid
expenses and other current assets
|
(387,189 | ) | (28,123 | ) | ||||
Accounts
payable, accrued liabilities and other current liabilities
|
(1,596,398 | ) | (190,541 | ) | ||||
Deferred
revenue
|
0 | (3,793,125 | ) | |||||
Deferred
project costs – net
|
0 | 319,902 | ||||||
Net
Cash Used In Operating Activities
|
(1,188,481 | ) | (3,244,731 | ) | ||||
Investing
Activities:
|
||||||||
Patent
costs
|
(16,402 | ) | 0 | |||||
Net
Cash Used In Investing Activities
|
(16,402 | ) | 0 | |||||
Financing
Activities:
Proceeds
from issue of common shares
|
0 | 49,975 | ||||||
Payments
on notes payable and other
|
0 | (10,433 | ) | |||||
Net
Cash Used In Financing Activities
|
0 | 39,542 | ||||||
Net
Decrease In Cash and Cash Equivalents
|
(1,204,883 | ) | (3,205,189 | ) | ||||
Cash
and Cash Equivalents, Beginning of Period
|
5,580,244 | 7,910,766 | ||||||
Cash
and Cash Equivalents, End of Period
|
$ | 4,375,361 | $ | 4,705,577 | ||||
Supplemental
Disclosure of Cash Flow Information
|
||||||||
Cash
paid during the year:
|
||||||||
Interest
paid
|
$ | 0 | $ | 183 | ||||
Income
taxes paid
|
$ | 266,000 | $ | 30,828 |